ThinkEquity Upgrades Anadys Pharma (ANDS) to Buy
More News related to ANDS
- Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
- Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
- Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
More News related to Upgrades
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Stocks Finish Higher After Tumultuous Session: Dow Up 21, Nasdaq Up 21, S&P 500 Up 6
- Swine Flu Cases Decline to Lowest Level in 2+ Months
- Geithner: 'quite high' chance unemployment will be under 10% in a year, says Goldman wrong in saying it didn't need US aid
- After Month's Of Gains, Gold Gives A Little Back Today (GDX, GLD, DGL, More)
ThinkEquity upgrades Anadys Pharma (Nasdaq: ANDS) from Accumulate to Buy with a $6 price target.
For more analyst ratings on ANDS click here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
Related Categories
UpgradesStocks Mentioned
-0.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
